FreeOx Biotech has signed an exclusive licence agreement to develop and exploit the product patent of the molecule Ox-02 with the Hospital Clinic Barcelona, the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and the Spanish National Research Council (CSIC), who own the patent.
Ox-02 is an innovative molecule with neuroprotective properties that are very beneficial for the treatment of ischaemic stroke. It was developed through years of research at the Functional Unit for Cerebrovascular Disease of the Hospital Clinic, led by Dr Ángel Chamorro, and the formulation study run by CIC biomaGUNE.
Recent preclinical studies using animal models run by Dr Anna Planas at the CSIC, have shown that Ox-02 has greater efficacy in some variables than its predecessor Ox-01 (in Phase IIb). The base of the two molecules is uric acid, but Ox-02 is integrated in a liposome capsule that boosts its effect by:
- Reducing oxidative stress
- Activating pleiotropic mechanisms
- Facilitating capillary perfusion
- Protecting the brain from the lesion caused by reperfusion
In certain patient groups with stroke, Ox-01 has shown an absolute benefit of up to 20% when compared to placebo of being free from permanent after-effects of the disease, and it is hoped that Ox-02 will exceed this.
Every year there are more than 13.7 million new ischemic strokes worldwide, according to the World Stroke Organization, and it is expected that one in four people over the age of 25 will suffer from a stroke during their lifetime.
The aim of FreeOx Biotech is for Ox-02 to reach the market in 2027 with a new neuroprotection and treatment paradigm for stroke through a partnership with the pharmaceutical industry.